Rasschaert, G., Peddle, A., Tejpar, S., West, N., Ross, J., Switzky, J. C., Edwards, K., Kari, G., Griffin, S., Luk, C. E., Cohen, D. N., Hammatt, E., Moon, E. (2025). AZUR-4, a phase 2, open label, randomized study of neoadjuvant dostarlimab plus capecitabine plus oxaliplatin (CAPEOX) versus CAPEOX alone in previously untreated T4N0 or stage III mismatch repair proficient/microsatellite stable resectable colon cancer.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps3649